Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan

References

• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12(4):364–375. doi:10.1007/s11892-012-0281-8
   PubMed Web of Science ®Google Scholar
• Noma H, Yasuda K, Shimura M. Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion. J Ophthalmol. 2019;2019:5185128. doi:10.1155/2019/5185128
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58(3):353–363.
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14). doi:10.1172/jci.insight.93751
   PubMed Web of Science ®Google Scholar
• Verma L, Chakravarti A, Gupta A, et al. One day wonder: fast resolution of macular edema following intravitreal ranibizumab in retinal venous occlusions. Indian J Ophthalmol. 2013;61(9):528–530. doi:10.4103/0301-4738.119458
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Jonas J, Paques M, Mones J, et al. Retinal vein occlusions. Dev Ophthalmol. 2010;47:111–135.
   PubMedGoogle Scholar
• Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127(4):374–380. doi:10.1001/archophthalmol.2009.14
   PubMedGoogle Scholar
• Khoramnia R, Figueroa MS, Hattenbach LO, et al. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1843–1856. doi:10.1007/s00417-021-05518-0
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol. 2012;250(11):1563–1571. doi:10.1007/s00417-012-2123-4
   PubMedGoogle Scholar
• AJMC. FDA approves faricimab to treat wet AMD and DME. AJMC; 2022 [ Updated February 1, 2022]. Available from: https://www.ajmc.com/view/fda-approves-fariximab-to-treat-wet-amd-and-dme. Accessed November 7, 2022.
   Google Scholar
• Sharma A, Kumar N, Kuppermann BD, et al. Faricimab: expanding horizon beyond VEGF. Eye. 2020;34(5):802–804. doi:10.1038/s41433-019-0670-1
   PubMed Web of Science ®Google Scholar
• Khanani AM, Guymer RH, Basu K, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1(4):100076. doi:10.1016/j.xops.2021.100076
   PubMedGoogle Scholar
• Nicolò M, Ferro Desideri L, Vagge A, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30(3):193–200. doi:10.1080/13543784.2021.1879791
   PubMed Web of Science ®Google Scholar
• Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23(16):9424. doi:10.3390/ijms23169424
   PubMed Web of Science ®Google Scholar
• Nair AA, Finn AP, Sternberg P Jr. Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy. Drug Des Devel Ther. 2022;16:3395–3400. doi:10.2147/DDDT.S368963
   PubMed Web of Science ®Google Scholar
• Rai BB, Morley MG, Zangmo P, et al. Surgical management of vitreo-retinal diseases in Bhutan: a 3-year national study. New Front Ophthalmol. 2020;6:1–6.
   Google Scholar
• Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 2012;32:1–8.
   Google Scholar
• Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15(2):100–110. doi:10.1097/00006982-199515020-00003
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non–indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128(3):443–452. doi:10.1016/j.ophtha.2020.08.006
   PubMed Web of Science ®Google Scholar
• Sivakumar P, Vedachalam R, Kannusamy V, et al. Barriers in utilisation of low vision assistive products. Eye. 2020;34(2):344–351. doi:10.1038/s41433-019-0545-5
   PubMed Web of Science ®Google Scholar
• Rai BB, Morley MG, Bernstein PS, et al. Pattern of vitreo-retinal diseases at the national referral hospital in Bhutan: a retrospective, hospital-based study. BMC Ophthalmol. 2020;20(1). doi:10.1186/s12886-020-01335-x
   Web of Science ®Google Scholar
• Rai BB, Sarac O, van Kleef JP, et al. Incidence and pattern of neuro-ophthalmological disorders presenting to vitreoretinal clinics in Bhutan: a 3-year national study. Clin Ophthalmol. 2023;17:107–114. doi:10.2147/OPTH.S396879
   PubMed Web of Science ®Google Scholar
• Lewallen S, Courtright P. Gender and use of cataract surgical services in developing countries. Bull World Health Organ. 2002;80(4):300–303.
   PubMed Web of Science ®Google Scholar
• TIO. Bhutan’s saviour. Bhutan News Service; 2012.
   Google Scholar
• Lin X, Lou L, Miao Q, et al. The pattern and gender disparity in global burden of age-related macular degeneration. Eur J Ophthalmol. 2021;31(3):1161–1170. doi:10.1177/1120672120927256
   PubMed Web of Science ®Google Scholar
• Colak ES, Majkic-Singh NT, Stankovic SS, et al. Gender associated lipid and apolipoprotein profile in patients with age-related macular degeneration. Ejifcc. 2011;22(1):16–23.
   PubMedGoogle Scholar
• Expectanxy.com W. Life expectancy in Bhutan; 2020. Available from: https://www.worldlifeexpectancy.com/bhutan-life-expectancy. Accessed December 19, 2022.
   Google Scholar
• Rai BB, Morley MG, Bernstein PS, et al. Severity of age-related macular degeneration at first presentation in Bhutan: a 3-year national study. BMC Ophthalmol. 2022;22(1). doi:10.1186/s12886-022-02520-w
   PubMed Web of Science ®Google Scholar
• Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol. 2016;16:142. doi:10.1186/s12886-016-0317-y
   PubMed Web of Science ®Google Scholar
• Fiebai B, Odogu V. Intravitreal anti vascular endothelial growth factor agents in the management of retinal diseases: an audit. Open Ophthalmol J. 2017;11:315–321. doi:10.2174/1874364101711010315
   PubMedGoogle Scholar
• Giri BR, Sharma KP, Chapagai RN, et al. Diabetes and hypertension in urban Bhutanese men and women. Indian J Community Med. 2013;38(3):138–143. doi:10.4103/0970-0218.116349
   PubMedGoogle Scholar
• World Health Organization. Non-Communicable Diseases: Country Profile 2018. World Health Organization; 2018.
   Google Scholar
• Pelzom D, Isaakidis P, Oo MM, et al. Alarming prevalence and clustering of modifiable noncommunicable disease risk factors among adults in Bhutan: a nationwide cross-sectional community survey. BMC Public Health. 2017;17:1.
   PubMed Web of Science ®Google Scholar
• Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014;2014:724780. doi:10.1155/2014/724780
   PubMed Web of Science ®Google Scholar
• Rai BB, Morley MG, Zangmo P, et al. Retinal laser services in Bhutan: a 3-year national survey. BMC Ophthalmol. 2020;20(1):404. doi:10.1186/s12886-020-01675-8
   PubMed Web of Science ®Google Scholar
• Rai BB, Shresthra MK, Thapa R, et al. Pattern and presentation of vitreo-retinal diseases: an analysis of retrospective data at a tertiary eye care centre in Nepal. Asia Pac J Ophthalmol. 2019;8(6):481–488. doi:10.1097/01.APO.0000604400.50700.2d
   PubMed Web of Science ®Google Scholar
• Rai BB, Essex RW, Morley MG, et al. Prevalence and severity of diabetic retinopathy at first presentation to vitreoretinal services in Bhutan: a 3-year national study. Jpn J Ophthalmol. 2023;67(3):287–294. doi:10.1007/s10384-023-00989-6
   PubMed Web of Science ®Google Scholar
• Rai BB, Ashby RS, French AN, et al. Rural-urban differences in myopia prevalence among myopes presenting to Bhutanese retinal clinical services: a 3-year national study. Graefes Arch Clin Exp Ophthalmol. 2021;259(3):613–621. doi:10.1007/s00417-020-04891-6
   PubMed Web of Science ®Google Scholar
• Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91(12):1573–1581. doi:10.1016/S0161-6420(84)34116-1
   PubMed Web of Science ®Google Scholar
• Fredette M-J, Giguere A, Anderson DR, et al. Comparison of matrix with Humphrey field analyzer II with SITA. Optom Vis Sci. 2015;92(5):527–536. doi:10.1097/OPX.0000000000000583
   PubMed Web of Science ®Google Scholar
• Cheung CM, Yang E, Lee WK, et al. The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2075–2085. doi:10.1007/s00417-015-2933-2
   PubMed Web of Science ®Google Scholar
• Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1):19–29. doi:10.1016/j.preteyeres.2009.10.001
   PubMed Web of Science ®Google Scholar
• Coscas G, Yamashiro K, Coscas F, et al. Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging. Am J Ophthalmol. 2014;158(2):309–318.e302. doi:10.1016/j.ajo.2014.05.004
   PubMed Web of Science ®Google Scholar
• Rai BB, Morley MG, Bernstein PS, et al. Profile of age-related macular degeneration in Bhutan: should screening be considered? Invest Ophthalmol Vis Sci. 2022;63(7):368–F0199.
   Web of Science ®Google Scholar
• Sepetis AE, Clarke B, Gupta B. Bilateral endophthalmitis following bilateral same-day anti-VEGF injections. Acta Ophthalmol. 2021;99(1):e131–e133. doi:10.1111/aos.14504
   PubMed Web of Science ®Google Scholar
• Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66–74. doi:10.1016/j.ophtha.2017.07.005
   PubMed Web of Science ®Google Scholar
• Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina. 2017;37(12):2341–2346. doi:10.1097/IAE.0000000000001488
   PubMed Web of Science ®Google Scholar
• Glombiewski JA, Nestoriuc Y, Rief W, et al. Medication adherence in the general population. PLoS One. 2012;7(12):e50537. doi:10.1371/journal.pone.0050537
   PubMed Web of Science ®Google Scholar
• Brady CJ, Garg S. Telemedicine for age-related macular degeneration. Telemed J E Health. 2020;26(4):565–568. doi:10.1089/tmj.2020.0011
   PubMed Web of Science ®Google Scholar